Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 0.59 |
| ▸ | ALB | P02768 | 2/20 | 0.59 |
| ▸ | PMAIP1 | Q13794 | 3/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170385 | 0.92 | MCL1 (0.66) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4165660 | 0.90 | MCL1 (0.73) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4163400 | 0.89 | MCL1 (0.71) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4164713 | 0.89 | MCL1 (0.70) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4168286 | 0.88 | MCL1 (0.58) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4172233 | 0.85 | MCL1 (0.57) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4154403 | 0.84 | MCL1 (0.82) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4165232 | 0.83 | MCL1 (0.63) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4176166 | 0.83 | MCL1 (0.83) | MCL1ALBPMAIP1BCL2L1BAD | |
| SCHEMBL4175214 | 0.81 | MCL1 (0.56) | MCL1ALBPMAIP1BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | claimed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | claimed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | claimed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| EP-3243814-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9035047-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8445679-B2 | 7-substituted indole MCL-1 inhibitors | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885ALB 3819/4885PMAIP1 67/4885 |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885ALB 3819/4885PMAIP1 67/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MCL1 1/4885ALB 3819/4885PMAIP1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.